

Special Issue

Metabolic Disorders and Inflammatory Bowel Diseases

Message from the Guest Editor

The interplay between metabolic disorders and inflammatory bowel diseases (IBD) has emerged as a critical field of investigation in recent years. Both conditions—encompassing obesity, diabetes, dyslipidemia, Crohn’s disease, and ulcerative colitis—share complex pathophysiological mechanisms involving chronic inflammation, immune dysregulation, and alterations in gut microbiota. Understanding these shared pathways offers promising opportunities for novel therapeutic and preventive strategies. This Special Issue aims to explore the bidirectional relationship between metabolic dysfunction and intestinal inflammation. We welcome the submission of original research articles, reviews, and clinical studies addressing metabolic alterations in IBD, the impact of gut microbiome composition on metabolic homeostasis, and the influence of diet, lifestyle, and pharmacological interventions on disease progression. Mechanistic studies that elucidate molecular signaling networks, cytokine pathways, or genetic predispositions are particularly encouraged.

Guest Editor

Dr. Fotios S. Fousekis

Department of Gastroenterology, University Hospital of Ioannina, 45500 Ioannina, Greece

Deadline for manuscript submissions

25 August 2026



Metabolites

an Open Access Journal
by MDPI

Impact Factor 3.7
CiteScore 6.9
Indexed in PubMed



mdpi.com/si/261409

Metabolites
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
metabolites@mdpi.com

[mdpi.com/journal/
metabolites](https://mdpi.com/journal/metabolites)





Metabolites

an Open Access Journal
by MDPI

Impact Factor 3.7
CiteScore 6.9
Indexed in PubMed



[mdpi.com/journal/
metabolites](https://mdpi.com/journal/metabolites)



About the Journal

Message from the Editor-in-Chief

The metabolome is the result of the combined effects of genetic and environmental influences on metabolic processes. Metabolomic studies can provide a global view of metabolism and thereby improve our understanding of the underlying biology. Advances in metabolomic technologies have shown utility for elucidating mechanisms which underlie fundamental biological processes including disease pathology. *Metabolites* is proud to be part of the development of metabolomics and we look forward to working with many of you to publish high quality metabolomic studies.

Editor-in-Chief

Dr. Amedeo Lonardo
Internal Medicine, Ospedale Civile di Baggiovara, Azienda Ospedaliero-
Universitaria, 41126 Modena, Italy

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Biochemistry and Molecular Biology) / CiteScore - Q2 (Endocrinology, Diabetes and Metabolism)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.7 days after submission; acceptance to publication is undertaken in 3.6 days (median values for papers published in this journal in the second half of 2025).